Pharmacology and Therapeutic Use of Calcitonin

Overview

Journal Drugs

Specialty Pharmacology

Date 1981 Apr 1

PMID 7014170

Citations 11

Authors

J C Stevenson

I M Evans

Affiliations

Soon will be listed here.

Abstract

Calcitonin is a peptide hormone secreted by the C-cells of the thyroid gland. A major physiological function of the hormone appears to be the protection of the skeleton against resorption in humans. It thus opposes the resorptive actions of parathyroid hormone and 1,25 dihydroxyvitamin D. This action is utilised pharmacologically in order to treat diseases where increased bone resorption is a major component. The efficacy of calcitonin in the treatment of Paget's disease of bone is well established, especially as it is currently the most effective agent in the treatment of the osteolytic form of the disease. In other bone diseases where resorption of bone is a component it is likely to be worthy of a trial of therapy. There are also sound theoretical reasons why calcitonin may be of benefit in the treatment of certain osteoporoses, especially in combination with other agents. Most recent studies would seem to support his view. A disadvantage of calcitonin therapy is that the hormone has to be administered parenterally, although future developments may obviate this. It is, however, a form of retreatment which is free of any long term serious side effects, and calcitonin now has a definite place in the management of specific bone and calcium disorders.

Citing Articles

Combined Therapy of Yishen Zhuanggu Decoction and Caltrate D600 Alleviates Postmenopausal Osteoporosis by Targeting FoxO3a and Activating the Wnt/-Catenin Pathway.

Li B, Jiang C, Zhan X Evid Based Complement Alternat Med. 2022; 2022:7732508.

PMID: 35873637 PMC: 9307327. DOI: 10.1155/2022/7732508.

Marine natural products that inhibit osteoclastogenesis and promote osteoblast differentiation.

El-Desoky A, Tsukamoto S J Nat Med. 2022; 76(3):575-583.

PMID: 35397769 PMC: 9165232. DOI: 10.1007/s11418-022-01622-5.

Zhuang-Gu-Fang Treats Osteoporosis in Ovariectomized Rats by Increasing the Osteogenesis-Related Factors Leptin, Ghrelin, and PYY.

Chen Y, Bai R, Chen W, Li S, Jiang Y Evid Based Complement Alternat Med. 2020; 2020:8164064.

PMID: 33281915 PMC: 7685821. DOI: 10.1155/2020/8164064.

Prolonged hypocalcemic effect by pulmonary delivery of calcitonin loaded poly(methyl vinyl ether maleic acid) bioadhesive nanoparticles.

Varshosaz J, Minaiyan M, Forghanian M Biomed Res Int. 2014; 2014:932615.

PMID: 24701588 PMC: 3950494. DOI: 10.1155/2014/932615.

Biopharmaceutical approaches for developing and assessing oral peptide delivery strategies and systems: in vitro permeability and in vivo oral absorption of salmon calcitonin (sCT).

Sinko P, Lee Y, Makhey V, Leesman G, Sutyak J, Yu H Pharm Res. 1999; 16(4):527-33.

PMID: 10227707 DOI: 10.1023/a:1018819012405.

References

August G, Shapiro J, Hung W . Calcitonin therapy of children with osteogenesis imperfecta. J Pediatr. 1977; 91(6):1001-5. DOI: 10.1016/s0022-3476(77)80916-5. View

Stevenson J, Evans I, Colston K, Gwee H, Mashiter K . Serum-prolactin after subcutaneous human calcitonin. Lancet. 1977; 2(8040):711-2. DOI: 10.1016/s0140-6736(77)90518-9. View

Ryan W . Treatment of Paget's disease of bone with mithramycin. Clin Orthop Relat Res. 1977; (127):106-10. View

Shiraki M, Oyama T, Uchiyama S, Ito H, Orimo H . Proceedings: Therapeutic effect of porcine calcitonin in senile osteoporosis. Calcif Tissue Res. 1974; 15(2):162. View

MacIntyre I . The action and control of the calcium-regulating hormones. J Endocrinol Invest. 1978; 1(3):277-84. DOI: 10.1007/BF03350394. View

Galante L, Colston K, MacAuley S, MacIntyre I . Effect of calcitonin on vitamin D metabolism. Nature. 1972; 238(5362):271-3. DOI: 10.1038/238271a0. View

Dunn V, CONDON V, Rallison M . Familial hyperphosphatasemia: diagnosis in early infancy and response to human thyrocalcitonin therapy. AJR Am J Roentgenol. 1979; 132(4):541-5. DOI: 10.2214/ajr.132.4.541. View

Jowsey J, Riggs B, GOLDSMITH R, Kelly P, Arnaud C . Effects of prolonged administration of porcine calcitonin in postmenopausal osteoporosis. J Clin Endocrinol Metab. 1971; 33(5):752-8. DOI: 10.1210/jcem-33-5-752. View

Gudmundsson T, MacIntyre I, Soliman H . The isolation of thyrocalcitonin and a study of its effects in the rat. Proc R Soc Lond B Biol Sci. 1966; 164(996):460-77. DOI: 10.1098/rspb.1966.0043. View

10.

Haas H, Dambacher M, GUNCAGA J, Lauffenbruger T . Renal effects of calcitonin and parathyroid extract in man. Studies in hypoparathyroidism. J Clin Invest. 1971; 50(12):2689-702. PMC: 292219. DOI: 10.1172/JCI106770. View

11.

De Bastiani G, Nogarin L, Perusi M . Pig calcitonin in the treatment of localised osteoporosis. Ital J Orthop Traumatol. 1976; 2(2):181-90. View

12.

Woodhouse N, JOPLIN G, MacIntyre I, DOYLE F . Radiological regression in Paget's disease treated by human calcitonin. Lancet. 1972; 2(7785):992-4. DOI: 10.1016/s0140-6736(72)92404-x. View

13.

Milhaud G, Hankiss J . [Inactivation of thyrocalcitonin by various organs]. C R Acad Hebd Seances Acad Sci D. 1969; 268(1):124-7. View

14.

Palmieri G, Dvorak J, BOTTOMLEY R . Letter: Calcitonin in steroid-induced osteoporosis. N Engl J Med. 1974; 290(26):1490-1. DOI: 10.1056/NEJM197406272902619. View

15.

Cantalamessa L, Catania A, Reschini E, Peracchi M . Inhibitory effect of calcitonin on growth hormone and insulin secretion in man. Metabolism. 1978; 27(8):987-92. DOI: 10.1016/0026-0495(78)90143-9. View

16.

de Luise M, Martin T, Greenberg P, Michelangeli V . Metabolism of porcine, human and salmon calcitonin in the rat. J Endocrinol. 1972; 53(3):475-82. DOI: 10.1677/joe.0.0530475. View

17.

Martin T, Robinson C, MacIntyre I . The mode of action of thyrocalcitonin. Lancet. 1966; 1(7443):900-2. DOI: 10.1016/s0140-6736(66)91577-7. View

18.

Marx S, Woodward C, Aurbach G . Calcitonin receptors of kidney and bone. Science. 1972; 178(4064):999-1001. DOI: 10.1126/science.178.4064.999. View

19.

Lorenc R, Tanaka Y, DeLuca H, Jones G . Lack of effect of calcitonin on the regulation of vitamin D metabolism in the rat. Endocrinology. 1977; 100(2):468-72. DOI: 10.1210/endo-100-2-468. View

20.

Altman R, JOHNSTON C, Khairi M, Wellman H, Serafini A, Sankey R . Influence of disodium etidronate on clinical and laboratory manifestations of Paget's disease of bone (osteitis deformans). N Engl J Med. 1973; 289(26):1379-84. DOI: 10.1056/NEJM197312272892601. View